- MindBio Therapeutics (CSE:MBIO), a pharmaceutical psychedelics stock, has made a major discovery about how psychedelic microdosing affects a patient’s speech
- The company determined whether or not patients had taken its lead drug candidate, the LSD derivative MB22001, by analyzing their speech using an artificial intelligence algorithm
- MindBio is a psychedelic biopharmaceutical stock creating treatments for mental health conditions
- MindBio Therapeutics stock has given back over 80 per cent since inception in 2023
MindBio Therapeutics (CSE:MBIO), a pharmaceutical psychedelics stock, has made a major discovery about how psychedelic microdosing affects a patient’s speech.
The company learned that it can determine if a patient has been dosed by analyzing their speech using an artificial intelligence (AI) algorithm, which could add value to the marketplace by enhancing patient adherence and clinician awareness.
MindBio’s discovery adds to its growing database of intellectual property (IP) around the dosing of its lead candidate drug, the LSD derivative MB22001, including blood data, speech data, EEG, ECG, DNA, psychological data and biophysical information collected from patient wearables.
According to Tuesday’s news release, the company’s proprietary algorithms analyze this IP, offering “an authoritative diagnostic and prescription tool to precision target and dose patients who are likely positive responders to MB22001.”
MindBio has initiated a go-to-market strategy for strategic aspects of its IP, part of which includes a letter of intent to acquire Life AI, a health AI technology company, for 35 million MindBio shares. Life AI is developing Booze AI, a speech-based smartphone app for alcohol intoxication detection scheduled to launch in the second half of 2025.
The acquisition offers highly-prospective opportunities to monitor medical adherence and further develop MindBio’s discovery about how psychedelics register in patient speech.
Leadership insights
“This discovery will enable the first commercialization of MindBio’s intellectual property whilst we conduct and await the results of multiple phase 2B clinical trials,” Justin Hanka, MindBio Therapeutics’ chief executive officer, as well as a director and shareholder of Life AI, said in a statement. “The acquisition of Life AI provides us with a platform to commercialize and monetize certain aspects of our technological IP across several health verticals and we are very excited by the upcoming product launch of Booze AI.”
About MindBio Therapeutics
MindBio is a psychedelic biopharmaceutical stock creating treatments for mental health conditions. Its lead drug candidate, MB22001, is a proprietary form of LSD designed for take-home microdosing. MB22001 has completed phase 1 clinical trials in 80 healthy participants and phase 2a clinical trials in patients with major depressive disorder, both yielding positive top-line data.
MindBio Therapeutics stock (CSE:MBIO) is up by 66.67 per cent trading at C$0.025 per share as of 9:46 am ET. The stock has given back over 80 per cent since inception in 2023.
Join the discussion: Find out what everybody’s saying about this psychedelics stock on the MindBio Therapeutics Corp. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image, generated by AI: Adobe Stock)